Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I - II Open Label Study of the Maximum Tolerated Dose, Safety and Efficacy of Docetaxel and Cisplatin Plus STI571 in Advanced Non-Small Cell Lung Cancer

NCT02127372 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT02127372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02127372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I - II Open Label Study of the Maximum Tolerated Dose, Safety and Efficacy of Docetaxel and Cisplatin Plus STI571 in Advanced Non-Small Cell Lung Cancer
Lead sponsor
Duke University
Phase
Phase 1/2
Overall status
Terminated
Start date
November 30, 2004
Completion date
December 31, 2010
Enrollment
43 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer